Human Clinical Data


Human Clinical Data

LIV Formula No. 1 has been evaluated across independent real-world and controlled human cohorts examining cardiometabolic biomarkers and functional outcomes.

Across these evaluations, a consistent pattern emerges centered on triglyceride metabolism, lipid handling, and cognitive performance.

Cardiometabolic Biomarkers

In a real-world cohort of 18 individuals, use of LIV Formula No. 1 was associated with consistent improvements in triglyceride-related lipid markers.

The most pronounced effects were observed in:

  • Triglycerides decreased from 217 → 131 mg/dL (−39.5%)
  • VLDL decreased from 43 → 23 mg/dL (−46.7%)

These changes represent the dominant signal across the dataset, indicating improved handling of triglyceride-rich lipoproteins.

Additional favorable changes were observed in atherogenic lipid markers:

  • LDL cholesterol decreased from 147 → 122 mg/dL
  • Non-HDL cholesterol decreased from 188 → 145 mg/dL

Reductions were also observed in small dense LDL, though this was not the primary driver of the overall lipid pattern.

Taken together, these findings suggest a shift toward a less atherogenic lipid profile, driven primarily by improvements in triglyceride metabolism rather than isolated changes in cholesterol levels.

Cognitive & Functional Outcomes

In a 12-week real-world evaluation, participants reported consistent improvements in measures related to cognitive function and day-to-day performance.

Reported changes included:

  • Mental clarity improved
  • Concentration improved
  • Focus improved
  • Mental task performance improved 
  • Mood improved
  • Brain fog decreased

These outcomes suggest that observed metabolic changes may translate into meaningful functional effects in daily life.

Integrated Interpretation

Across independent evaluations, including real-world use and controlled 12-week observation, LIV Formula No. 1 demonstrates a consistent metabolic signature centered on triglyceride-rich lipoprotein metabolism.

The most reproducible findings include reductions in triglycerides and VLDL, with parallel improvements in lipid markers associated with atherogenic risk.

Notably, these effects occur with minimal change in LDL levels, suggesting a mechanism distinct from traditional cholesterol-lowering approaches.

The consistency of this pattern across cohorts, and its strengthening over time, supports a system-level effect related to hepatic lipid handling and metabolic flux.

These findings are observational in nature and should be interpreted within that context.

Safety Snapshot

Across evaluations, LIV Formula No. 1 was well tolerated, with:

  • No reported serious adverse events
  • No clinically meaningful changes in liver or kidney markers
  • No evidence of metabolic disruption

Observed differences in blood pressure were relative to screening values and not indicative of a treatment effect.

Overall, LIV Formula No. 1 was well tolerated with no clinically meaningful safety signals observed.